ClinicalTrials.gg
RecruitingNCT07304778glUCModel-1Updated Jan 6, 2026

Evaluation of a Mobile AI-powered Decision Support System for Insulin Dosing and Glucose Prediction in Type 1 Diabetes: The glUCModel Clinical Trial Protocol

An interventional study of glUCModel app in Diabetes (Insulin-requiring, Type 1 or Type 2), sponsored by Universidad Complutense de Madrid. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Universidad Complutense de Madrid · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Jul 2025, registered Nov 2025).
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 254 studies in Diabetes Mellitus with a site in Spain — 20 open to participants now, 29 under way, 5 of them phase 3. Diabetes Mellitus · Spain.

Planned enrollment
194th of 211
34 · median 394
Started
2025
with 9 others
No phase
65 of 254
11 open now
Primary completion
2026-02
later than 11 of 28 live
Registered
245th of 254
by date
Lead sponsor
6 of 254
Universidad Complutense de Madrid

Among the 254 studies in Diabetes Mellitus with a site in Spain, this one is the 194th largest by planned enrollment of the 211 interventional ones that give a count, is one of 10 that started in 2025, is one of 65 with no phase, reaches primary completion later than 11 of the 28 other live ones, and was the 245th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

20 of the 254 studies in Diabetes Mellitus with a site in Spain are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 254 studies in Diabetes Mellitus with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety and efficacy of integrating predictive models into insulin therapy management via the user-centered glUCModel mobile app in People with Type 1 Diabetes Mellitus following Multiple Insulin Dosing therapy. Participants will be aged 18 to 65 years. The main questions it aims to answer are:

Does using the app improve glycaemic control, as measured by time in range? Does using the app reduce the number of episodes of hyperglycaemia and hypoglycaemia? Are the app's design and functionality adequate?

The study will comprise four phases:ses}):

  • Screening phase: Informed consent, collection of sociodemographic and clinical data, and baseline Pittsburg, IFIS, and DTSQ questionnaires.
  • Run-in phase: 2 weeks of standard care with CGM. Data will be used to generate personalized predictive models in the intervention group.
  • Active treatment phase: Participants continue MDI therapy. The intervention group will additionally use the glUCModel mobile app. CGM data from the final 2 weeks will be analyzed.
  • Evaluation and analysis phase: Participants will complete the uMARS, Pittsburgh, and DTSQ questionnaires. Statistical analysis and correlations among outcomes will be processed.
Read the detailed description

Diabetes mellitus is a chronic, metabolic disorder characterized by impaired regulation of blood glucose, affecting more than 400 million people worldwide. Insulin, a hormone produced by the pancreas, facilitates the uptake of glucose into cells for energy production. In diabetes, either insufficient insulin is produced or the body cannot use it effectively, leading to persistent hyperglycemia. Over time, uncontrolled glucose levels can result in serious complications, including cardiovascular disease, neuropathy, retinopathy, and nephropathy. Effective management is therefore essential to prevent both acute and long-term adverse outcomes.

Two main forms of diabetes can be distinguished. Type 1 diabetes mellitus (T1DM) is an autoimmune condition in which pancreatic β-cells are destroyed, resulting in absolute insulin deficiency. It accounts for approximately 10% of all cases. Individuals with T1DM require lifelong insulin replacement therapy, typically delivered as multiple daily injections (MDI) or via an insulin pump. In contrast, type 2 diabetes mellitus (T2DM), the more prevalent form, is characterized primarily by insulin resistance. While insulin production is preserved in early stages, progressive dysfunction may ultimately necessitate pharmacological therapy, including insulin. Lifestyle interventions such as healthy diet and physical activity can delay or prevent T2DM onset and progression.

For individuals with diabetes, day-to-day self-management requires frequent glucose monitoring and insulin dose adjustments that must take into account meals, physical activity, stress, illness, and other factors. Capillary glucose meters and, more recently, continuous glucose monitoring systems (CGMs) have greatly improved access to real-time glucose data. However, interpreting these data and deciding on corrective actions remains challenging, and errors in insulin dosing can lead to hypoglycemia or persistent hyperglycemia. Both acute complications and the constant decision-making load contribute to reduced quality of life and treatment fatigue.

To support patients in these complex tasks, predictive models of glucose dynamics have been extensively investigated. Accurate prediction could enable early warnings of hypo- or hyperglycemia and assist in optimizing insulin therapy. The ultimate vision is the development of a fully automated ''artificial pancreas'' combining glucose sensing, insulin delivery, and robust prediction algorithms. Various machine learning (ML) approaches have been explored for glucose forecasting, including Genetic Programming , K-Nearest Neighbours , Grammatical Evolution, and, most prominently, Neural Networks. Among neural architectures, Long Short-Term Memory (LSTM) and other recurrent models have demonstrated strong performance for time-series data such as CGM traces, although convolutional and multilayer perceptron (MLP) networks have also been applied. Despite encouraging results, challenges remain in ensuring accuracy, robustness, and real-world usability across diverse patient populations.

Managing T1DM, particularly in patients using MDI, continues to pose a major challenge. While CGM and insulin pumps have improved outcomes, decisions about insulin dosing still depend heavily on patient intuition and experience, leaving room for error and variability. There is therefore a clear need for decision-support tools that combine predictive analytics with personalized recommendations to enhance safety, autonomy, and treatment adherence.

The glUCModel mobile application was developed to address this need. Since its early versions, it integrates proprietary, patented artificial intelligence models to provide real-time insulin recommendations, short-term glucose forecasts, and predictive alerts for hypo- and hyperglycemia. With a forecast horizon of up to two hours, the system aims to reduce glycemic variability and support timely corrective actions.

This protocol describes a randomized, open-label clinical study to evaluate the efficacy and safety of the glUCModel application in patients with T1DM using MDI therapy. The primary objective is to assess improvement in short-term glycemic control, measured by the percentage of time spent in target range (70-180 mg/dL). Secondary objectives include reductions in glycemic excursions, improved treatment satisfaction, and evaluation of usability and adherence in a real-world setting.

03

Conditions studied

  • Diabetes (Insulin-requiring, Type 1 or Type 2)

Browse trials for

Keywords

  • Diabetes
  • Bolus recomendation
  • Artificial Intelligence
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • \< 9%
  • Currently following an MDI Bolus-Basal therapy.

    • Wearing CGMs connected to a mobile phone.
    • Spanish language proficiency.
    • Willingness to participate in the trial.
    • At least one year since the time of diabetes diagnosis.
    • Ability to use a mobile application like glUCModel.
    • Own a mobile phone running Android or iOS operating system.
    • Ability to follow a Portion-controlled diet for diabetes.
    • Educated to do an active management of insulin dosing

Exclusion criteria

Exclusion Criteria:

  • \< 9%.
  • Not wearing CGMs.
  • Non-Spanish language proficiency.
  • Less than one year since the time of diabetes diagnosis
  • Unable to use a mobile application like glUCModel
  • Unable to follow a Portion-controlled diet for diabetes
  • Unable to do an active management of insulin dosing.
  • Diagnosed with a significant psychiatric disorder.
  • Subjects in treatment with corticoids
  • Patients who have required hospitalization or surgery in the last six months.
  • Pregnancy or planning a pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants continue MDI therapy. The intervention group will additionally use the glUCModel app. CGM data from the final 2 weeks will be analyzed

    Other: glUCModel app

  • No intervention
    Control

    Participants continue MDI therapy. CGM data from the final 2 weeks will be analyzed

Interventions

  • OtherglUCModel app

    The intervention consists on using glUCModel, an application designed to help people with diabetes. It features a suite of artificial intelligence tools and statistical techniques for capturing and managing key information that people with diabetes need to track, as well as for predicting glucose values to aid users in informed decision-making.

06

What researchers measure

Primary outcomes

  1. Time in Range (TIR)

    Time in Range (TIR), defined as the percentage of time that interstitial glucose is between 70-180 mg/dL during the final 2 weeks of the intervention phase

    Time frame: During the last 2 weeks of intervention

  2. Usability and adherence

    Patient-reported outcomes on usability and adherence through uMARS. The usability of the app will be evaluated using the Spanish Version of the User Version of the Mobile Application Rating Scale (uMARS). This scale provides a comprehensive and objective measure of app usability and consists of 20 items. Each item is rated on a 5-point scale, ranging from 1 (inadequate) to 5 (excellent).

    Time frame: Two weeks

Secondary outcomes

  1. Frequency of Level 1 hypoglycemia

    Frequency in minutes of Level 1 hypoglycemia (40 ≤ CGM glucose \< 55).

    Time frame: During the last 2 weeks of intervention

  2. Frequency of Level 2 hypoglycemias

    Frequency in minutes of Level 2 hypoglycemia (55 ≤ interstitial glucose ≤ 70)

    Time frame: During the last 2 weeks of intervention

  3. Frequency of Level 1 hyperglycemias

    Frequency in minutes of Level 1 hyperglycemia (180 ≤ CGM glucose ≤ 240).

    Time frame: During the last 2 weeks of intervention

  4. Frequency of Level 2 hyperglycemias

    Frequency in minutes of Level 2 hyperglycemia (241 ≤ interstitial glucose ≤ 400).

    Time frame: During the last 2 weeks of the intervention

  5. Duration of Level 1 hypoglycemias

    Average Duration in minutes of Level 1 hypoglycemia (40 ≤ CGM glucose \< 55)

    Time frame: During the last 2 weeks of intervention

  6. Duration of Level 2 hypoglycemia

    Average duration in minutes of Level 2 hypoglycemia (55 ≤ interstitial glucose ≤ 70).

    Time frame: During the last 2 weeks of intervention

  7. Duration of Level 1 hyperglycemias

    Average duration in minutes of Level 1 hyperglycemia (180 ≤ CGM glucose ≤ 240).

    Time frame: During the last 2 weeks of intervention

  8. Duration of Level 2 hyperglycemias

    Average duration in minutes of Level 2 hyperglycemia (241 ≤ interstitial glucose ≤ 400).

    Time frame: During the last 2 weeks of the intervention

  9. Glycemic coefficient of variation

    Coefficient of Variation (CV) is calculated using the mean and the standard deviation of the glucose values. Coefficient of Variation (CV) is calculated by dividing the Standard Deviation by the mean of the glucose values.

    Time frame: During the last 2 weeks of intervention

  10. Glycemic variability

    Glycemic variability is computed as the standard deviation. Standard Deviation (SD) is measured as the dispersion of glucose values from the average.

    Time frame: During the last 2 weeks of intervention

  11. Accepted Recommendations

    Percentage of insulin recommendations accepted and applied by the user from the total number of recommendations requested.

    Time frame: During the last 2 weeks of intervention

  12. Quality of predictions

    Quality of predictions measured using the Parkes Errod Grid analysis.

    Time frame: During the last 2 weeks of intervention

  13. Treatment satisfaction

    Treatment satisfaction using the Diabetes Treatment Satisfaction Questionnaire (DTSQ)

    Time frame: last 2 weeks of the intervention

Other outcomes

  1. Sleep Quality before the intervention

    We will evaluate Sleep Quality before and after the intervention. The Pittsburg Sleep Quality Index (PSQI) will be used. The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties. https://www.sleep.pitt.edu/psqi

    Time frame: The day of the start of the intervention

  2. Sleep Quality after the intervention

    We will evaluate Sleep Quality before and after the intervention. The Pittsburg Sleep Quality Index (PSQI) will be used. The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that assesses sleep quality and disturbances over a 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The sum of scores for these seven components yields one global score. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties. https://www.sleep.pitt.edu/psqi

    Time frame: Two weeks after the day of the end of the intervention

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — It depends on the autorization of the University

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Feb 2026, 6 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 6 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2025
First posted
Dec 26, 2025
StartActual
Jul 11, 2025
Primary completionEst.
Feb 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07304778
Collaborators
Bioinspired Intelligence SL, Hospital de Toledo
Responsible party
J. Ignacio Hidalgo (Full Professor, Universidad Complutense de Madrid) — Principal investigator
First posted
Dec 26, 2025
Start date
Jul 11, 2025
Primary completion
Feb 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Jan 6, 2026

Study contacts

Ignacio Hidalgo, PhD
Contact
hidalgo@dacya.ucm.es
+34679562712

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion